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FingerprintIn childhood the neuronal ceroid lipofuscinoses (NCL) are the most frequent lysosomal diseases and the most fre-
quent neurodegenerative diseases but, in adulthood, they represent a small fraction among the neurodegenerative
diseases. Their morphology is marked by: (i) loss of neurons, foremost in the cerebral and cerebellar cortices
resulting in cerebral and cerebellar atrophy; (ii) an almost ubiquitous accumulation of lipopigments in nerve
cells, but also in extracerebral tissues. Loss of cortical neurons is selective, indiscriminate depletion in early child-
hood forms occurring only at an advanced stage, whereas loss of neurons in subcortical grey-matter regions has
not been quantitatively documented. Among the fourteen different forms of NCL described to date, CLN1 and
CLN10 are marked by granular lipopigments, CLN2 by curvilinear proﬁles (CVPs), CLN3 by ﬁngerprint proﬁles
(FPPs), and other forms by a combination of these features. Among extracerebral tissues, lymphocytes, skin,
rectum, skeletal muscle and, occasionally, conjunctiva are possible guiding targets for diagnostic identiﬁcation,
the precise type of NCL then requiring molecular analysis within the clinical and morphological context.
Autosomal-recessive adult NCL has been linked molecularly to different childhood forms, i.e. CLN1, CLN5,
and CLN6, whilst autosomal-dominant adult NCL, now designated as CLN4, is caused by a newly identiﬁed
separate gene, DNAJC5. This article is part of a Special Issue entitled: The Neuronal Ceroid Lipofuscinoses or
Batten Disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Morphologically, the neuronal ceroid lipofuscinoses (NCL) are
marked by two features: (i) loss of nerve cells in the brain and retina
and (ii) accumulation of intracellular lipopigments, especially in neu-
rons. Depletion of neurons in NCL affects primarily the cerebral andNCL; ANCL, adult-onset NCL;
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rights reserved.cerebellar cortices; quantifying studies concerning subcortical grey
matter regions and nuclei have not yet been performed but, if present
at all, depletion is more subtle. The degree of neuronal depletion is in-
versely proportional to the length of the disease and proportional to
the onset of clinical symptoms. Loss of nerve cells outside of the
brain and the retina is, likewise, not well-documented. The reason
for the preferential loss of cortical neurons in NCL is still ill-understood.
Moreover, the examiner of NCL patients' central nervous system (CNS)
has to be aware of the fact that at autopsy the pathology in the CNS and
the retina is at end-stage, allowing little analysis of the morphological
evolution of the condition such as early and/or preferential loss of neuro-
nal populations and types of neurons in the CNS. Even so, in the brains of
juvenile and adult NCL patients it appears that small neurons in the cortex
are earlier and more severely depleted than the larger, e.g. pyramidal,
ones whilst accumulation of lipopigments is more prominent in large
neurons, again pyramidal cells of the cerebral cortex — but not in large
Purkinje cells of the cerebellum. Post-mortem studies have revealed
that in the cerebral cortex neuronal degeneration starts at the dendritic
proﬁle inducing a microglial reaction whilst the neuronal perikaryon is
still present. In the retina, neuronal depletion commences in the outer
layer, i.e. in the photoreceptor outer segments, followed by that of the
inner segments and then, of nerve cell bodies from where the process
proceeds inward towards the ganglionic layer. Pigmented epithelial
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neuronal retinal layers.
Whilst a complete picture of the CNS pathology can only be
ascertained at autopsy, many diagnostic studies by brain biopsy, usu-
ally of the cerebral cortex, have focused on the accumulation of
lipopigments as a diagnostic marker but they have contributed little
to our understanding of true structural damage. Most diagnostic
brain biopsy investigations were carried out before wide-spread ac-
cumulation of lipopigments in extracerebral tissues had been
recognised, and have now been superseded by those of skin, rectum,
skeletal muscle and even blood lymphocytes. This shift in diagnostic
material from CNS to non-CNS tissues had already occurred in the
pre-molecular era and, thus, before the advent of immunohisto-
chemistry which might otherwise have gainfully been applied to
biopsied brain tissue. Thus, retrospective investigations on archival
CNS tissue may provide new information, especially on early-onset
NCL but, to our knowledge, no such study has been performed. A
large ultrastructural spectrum of lipopigment morphology was iden-
tiﬁed in brain biopsies but this has not been signiﬁcantly further ex-
panded by studies on extracerebral tissues. These studies were
executed largely by transmission electron microscopy (EM), requiring
rapid ﬁxation in glutaraldehyde for optimum morphological preserva-
tion, rendering further investigative procedures almost impossible.
Hence, there is a potential gap in our understanding of detail that
might otherwise be obtainable by immunohistochemistry such as the
identity of new proteins accruing within lipopigments. Likewise, ultra-
structural study of lipopigments in the brain, apart from those in
cerebro-cortical diagnostic biopsies, has only scantily been investigated
[1]. Lipopigments as lysosomal residual bodies, with the intralysosomal
metabolism almost completed, are rather resistant to agonal and post
mortem autolysis, thus comprehensive ultrastructural studies of CNS
lipopigments in subcortical grey and white matter as well as the retina
may prove useful.
These considerations attest to the view that, despite a decline in
morphological studies on the CNS in NCL, there are still areas that
might be gainfully explored with modern immunohistochemical tech-
niques in the human NCL brain.
2. Neuropathology of the central nervous system
2.1. Childhood forms of NCL
Whilst many independent studies published over several decades
have reported on CNS neuropathology in the classical childhood
forms of NCL, i.e. CLN1, CLN2, and CLN3, studies concerning CNS neu-
ropathology in the more recently delineated NCL forms are few and
not always comprehensive. For instance, of the two forms of CLN8,
the late-infantile variant and the northern epilepsy (EPMR), only few
of the latter group have been reported [2]. Likewise, of CLN10, constitut-
ing a congenital form aswell as a post-infantile one, only publications of
the congenital form are available for CNS tissue from the pre-molecular
era [3].
2.1.1. Macroscopy
Macroscopically, the brain is almost always reduced in size, fre-
quently resulting in microcephaly in CLN1 and CLN10, although
this is not seen in all patients in the EPMR variant of CLN8 who
reached adulthood [2]. Increasing severity of brain atrophy is ap-
parent not only between early and late onset forms of childhood
NCL, i.e. CLN1 and CLN3, but also with progression of the disease
in the same CLN group, e.g. CLN6, having for instance a brain
weight of 883 g (control: 1263 g) at age 7 years and of 450 g (con-
trol: 1400 g) at age 13 years [4]. Reduction in brain weight is chief-
ly due to cerebral cortical atrophy accompanied by a reduction in
white matter, and enlargement of cerebrospinal ﬂuid-carrying
spaces, the subarachnoid space and the ventricles, and to a varyingdegree, atrophy of the cerebellum, particularly in CLN1 and CLN2 but
also, variably, in the other childhood forms.
2.1.2. Light microscopy
Preferential loss of neurons has been described for small neu-
rons of layer II in CLN3 [5,6], in layers III and V in CLN2 [7], in
mid-layers in CLN6 [4], and in layer V in CLN7 [8]. Detailed micro-
scopic and immunohistochemical studies performed on the human
hippocampus in childhood forms of NCL [9] show relatively minor
neuronal depletion and lipopigment formation in the CA-1 sector
as well as sparing of calretinin-positive interneurons and microglial
activation. In juvenile NCL (JNCL), the substantia nigra often lacks
pigment because of neuronal loss which may explain Parkinsonian
features encountered in these patients. There is loss of Purkinje
cells and granular cells in the cerebellum, of granular cells in the
dentate nucleus, whilst subcortical grey matter in the cerebrum,
the brainstem and spinal cord is not strikingly depleted of nerve
cell bodies. Depletion of neurons is accompanied and followed by
activation of microglia, the presence of lipopigment-containing
macrophages and astrocytes, the latter forming a glial ﬁbrillary
network or ﬁbrillar gliosis. Activated microglia in areas where neu-
ronal loss is not yet obvious may indicate the commencement of mor-
phological damage indicating degeneration of dendritic processes at the
periphery of neurons.
Atrophy of the retina is particularly pronounced in CLN1 and
CLN3, less so in CLN2, but also present in the late-infantile variants
CLN5 [7], CLN6 [4] and CLN7 [8] whilst apparently nothing has been
described of the retinal pathology in CLN8, CLN9 [10], and CLN10. Oc-
casionally, the progression of atrophy from the photoreceptor layer to
the ganglionic layer is not apparent, such as in patients with CLN5 [7].
Gliosis of varying degrees and the presence of macrophages mark the
atrophic retina.
Conspicuous accumulation of lipopigments occurs in nerve cell
bodies, often extending into the proximal axonal segments or axon
hillocks, terminal axonal spindles or meganeurites. By light micros-
copy (LM), the lipopigments appear brownish in haematoxylin–
eosin-stained sections, imparting a mild brownish hue to the grey
matter at gross inspection. These lipopigments stain with periodic
acid-Schiff (PAS) and appear bluish when stained with luxol-fast
blue (LFB). Their lipid content may also give a black appearance in
Sudan black stain and a reddish appearance in oil red-O stain. How-
ever, the ‘lipid droplets’ may not be or may partially not be lipids as
revealed by lipofuscin studies in equine thyroid glands: “We looked
at lipid droplets in lipofuscin in the equine thyroid gland. Here sim-
ilar structures are not lipid but caused by infusion of colloid droplets
(i.e. soluble protein) with the hydrophobic condensed matrix that
made up the lipofuscin pigment. As with the thyroid pigment it
may just be a watery vesicle partly embedded in the proteolipid/
lipid matrix with the oily appearance due to the varying density of
the matrix as seen through the thickness of the section.” (Robert D.
Jolly, personal electronic communication, October 18, 2012, to co-author
H.H.G.).
2.1.3. Electron microscopy
Autoﬂuorescence and EM may also reveal accumulation of
lipopigments in dendritic processes. Cerebrocortical, subcortical,
and cerebellar neurons as well as those of the brainstem and the spinal
cord are varyingly affected, with granular ultrastructure in CLN1 and
CLN10, curvilinear proﬁles (CVPs) in CLN2 and mixed CVP, rectilinear
(RLP), and FPPs in the remaining CLN forms. Astrocytes, ependymal
cells, and choroid plexus epithelial cells may harbour lipopigments,
oligodendroglia are said to be sparsely affected but phagocytosed
lipopigments are evident in macrophages. Neuronal perikarya of
dorsal root ganglia and other peripheral nerve cell clusters may
also display lamellar inclusions resembling the membranous cyto-
plasmic bodies seen in the gangliosidoses [1].
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Immunohistochemistry reveals thepresence of abundant sphingolipid
activator proteins (SAPs) in CLN1 and CLN10 whilst subunit C of mito-
chondrial ATP synthase (SCMAS) prevails in the lipopigments of other
CLN forms. A minor component of either SAPs or SCMAS may also be
encountered in the forms of CLN where the other component dominates
the picture. The amyloid precursor protein and beta-A4 amyloid protein
may also, though rarely, be seen within lipopigments [2,11]. Lysosomal
proteins, such as palmitoyl protein thioesterase 1 (PPT1), tripeptidyl pep-
tidase 1 (TPP1), and cathepsinD (pCTSD)may be encountered alongwith
the lipopigments, except in the CLN forms where they are deﬁcient by
mutations, i.e. PPT1 in CLN1, TPP1 in CLN2, and CTSD in CLN10.
3. Adult NCL
Several aspects render adult NCL a special form among the differ-
ent age-related forms of NCL. It is much rarer than the childhood
forms. On a hereditary basis, it may follow autosomal-recessive or
autosomal-dominant traits of inheritance whilst sporadic cases
have also been encountered. A precise nosological diagnosis in
non-recessive forms requires autopsy. Whilst all childhood forms
of NCL follow an autosomal-recessive mode of inheritance, families
with autosomal-dominant adult NCL have now been described,
some of them associated with mutations in a newly identiﬁed gene,
DNAJC5. One of the neuropathological hallmarks of childhood NCL,
loss of neurons, may not be quite so obvious in adult NCL. Final noso-
logical diagnosis of adult NCL may remain equivocal in certain pa-
tients;CNS neurons which have accumulated considerable amounts
of lipopigments, may not easily be identiﬁed as having adult NCL
since, with increasing age of the patient, lipopigments may accrue
in non-NCL lysosomal diseases, such as mucopolysaccharidoses or
GM1-gangliosidosis. This uncertainty or even inaccuracy may in-
crease when only biopsy data from extracerebral tissue are available
for diagnosis.
Recently, adult patients with familial NCL have been found to have
homozygous or compound heterozygous mutations and have, there-
fore, been genetically assigned to childhood forms of NCL. When such
patients with pre-adult onset of equivocal symptoms and protracted
forms have to be distinguished from those with true adult-NCL, the
absence of visual deﬁcits (clinically and fundoscopically the hallmark
of true adult-onset NCL (ANCL)) may aid in further identifying adult
NCL since even subtle retinal abnormalities have not been documented
in adult NCL of the CLN1 type [12].
3.1. Adult autosomal-recessive type of NCL
Whilst adult-NCL families, usually siblings, suggestive of having
autosomal-recessive inheritance have been described in the premolecular
era, those successfully identiﬁed with homozygous or compound het-
erozygous mutations belong to CLN1 ( although patients with muta-
tions in the CLN1 gene and lack of PPT1 enzyme activities have been
diagnosed without autopsy), CLN5 [13], and CLN6 [14,15]. Although
clinical abnormalities and evidence of retinal atrophy are absent, ret-
inal neuronal perikarya may accumulate NCL-speciﬁc lipopigments
[16,17], even in CLN5 adult NCL [13].
The second neuropathological hallmark of childhood NCL, the
intraneuronal accretion of lipopigments, is also the hallmark of adult
NCL, enlarging the neuronal perikarya and often forming proximal
axon spindles or meganeurites replete with lipopigments. Even in the
cerebral and cerebellar cortices neuronal loss may be mild or minimal
and, thus, major gross atrophy of the brain may be absent. FPPs may
be conspicuous within the neuronal lipopigments, and have been
reported both at post mortem [13] and in brain biopsy [18]. A granular
component is also often present whilst CVPs are rare or absent. The
lipopigments contain, by immunohistochemistry, SCMAS and, to alower degree, SAPswhilst beta-A4 amyloid aswell as amyloid precursor
protein have also been demonstrated [10].
The SGSH and CLCL6 genes found in mucopolysaccharidosis IIIA
(MPS IIIA) and a mousemodel for lysosomal storage [19] respectively,
have been assigned to NCL mutations but this link remains controver-
sial. A patient who was compound heterozygous, i.e. with E355K and
S298P mutations, had too little morphological details reported [20] to
clearly identify the ultrastructure of the lysosomal residual bodies,
being either vacuolar as in MPS IIIA, or of lipopigment nature, as in
NCL. The combination of MPS IIIA and accretion of lipopigments in
the cerebral cortex at autopsy, strikingly like in NCL, has previously
been reported [11]. Likewise, the concomitant accumulation of
lipopigments has also been encountered in other lysosomal storage
diseases. Of the reported ANCL patients with only single heterozy-
gous CLCL6 mutations [19], one was reported without any morpho-
logical details whilst the second patient was later found to have
compound heterozygousmutations in the CLN5 gene [13]. This suggests
that at least the second case, with a sole heterozygous mutation in the
CLCL6 gene, might have just been a carrier of a heterozygous CLCL6
gene but not an NCL patient.
Recently four siblings who had NCL and Parkinsonian features were
found to have the homozygous mutation in the ATP13A2 gene found in
CLN12. Autopsy studies revealed NCL-speciﬁc lipopigment accumula-
tion in neuronal and glial cells of the cerebral and cerebellar cortices,
in the basal ganglia and in the retina [21].
3.2. Adult autosomal-dominant type of NCL
To date, only adult familial NCL has been reported to carry an
autosomal-dominant trait of inheritance. The bases for diagnosing
such patients with autosomal-dominant adult NCL (ADANCL) are
clinical symptoms and accretion of lipopigments in neuronal perikarya,
very rarely in extracerebral tissues and, then, often difﬁcult to distin-
guish from regular lipofuscin. At autopsy, the brain weight may be re-
duced (although not always [22]), below 1200 g [23] or, rarely, even
under 900 g [24], whilst the cerebellum may be severely atrophic.
Loss of cerebrocortical neurons is not always visible. However, Purkinje
and granular cells in the cerebellum may be severely reduced in num-
ber. Repeated studies have also shown that neurons of the substantia
nigra are depleted [23,24], and there is an accompanying loss of
neuromelanin. Sometimes, loss of neurons in the substantia nigra was
considered severe [25], consistent with the morphology associated
with clinical Parkinsonian features. Neuronal loss was also observed in
cerebellar nuclei and the inferior olives [25].
Neuronal depletion appears to lead to cellular and ﬁbrillar
astrocytosis. Lipopigments, characterised by autoﬂuorescence and PAS-
positive staining, were encountered in innumerable neurons of the
cerebral cortex, subcortical grey matter of the brain and brainstem
as well as the spinal cord whilst cerebellar neurons were less heavily
affected. Apart from neuronal perikarya, proximal axonal segments
were also ﬁlled with lipopigments as were occasional Purkinje cell
dendrites [24]. Lipopigment formation has been encountered in se-
lective neuronal populations; the CA-e region of the hippocampus
and in neurons of the fascia dentata. In some patients lipopigments
formed larger so-called myoclonus bodies [22,26]. Neuroﬁbrillary
tangles and amyloid plaques were largely missing although, occa-
sionally, can be demonstrated with tau-antibodies in neurons of
the cerebellar nuclei and substantia nigra [24].
3.3. Immunohistochemistry
By immunohistochemistry, SAPs were detected regularly in the
lipopigments and, more rarely, SCMAS [24]. Increasedmicroglial activi-
ty was seen in several subcortical grey matter areas, such as basal
ganglia, thalamus, inferior olives, and brainstem nuclei [24].
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By EM, the overwhelming pattern was that of granular osmiophilic
deposits (GRODs) but, occasionally, also FPPs [24,25,27].
When successfully tested by molecular analysis, mutations in the
DNAJC5 gene were found [22–29]. Retinopathological data in ADANCL
have not yet been reported.
4. Pathology of extracerebral tissues
4.1. Historical annotations
Advances in histochemistry and EM of brain biopsies for diagnostic
purposes in the late 1960s and early 1970s led to the identiﬁcation of
NCL as an independent disease group among the storage diseases of
childhood [30,31]. This was followed by a classiﬁcation of NCL based
on the age of clinical onset and cytosome ultrastructure [32]. At the
same time, EM investigations of extra-cerebral tissues in neurodegener-
ative diseases became feasible, and proved particularly useful for NCLs
(as compared to other storage diseases (reviewed in [33])).
The ﬁrst report on the involvement of extracerebral tissues in NCL
was by Joosten et al. in 1973 [34], who examined sural nerve biopsies
of 2 children affectedwith “amaurotic idiocy”. In the same year, cytoplas-
mic inclusions were reported in the vermiform appendix and skeletal
muscle of 10 NCL patients [35], and subsequently the usefulness of mus-
cle biopsies in NCL was reviewed by Goebel et al. [36]. The search for
straightforward, easy-to-perform and less invasive diagnostic ap-
proaches led to ultrastructural examination of circulating lymphocytes
in late-infantile NCL (LINCL) [37], and to the study of vacuolated lympho-
cytes in JNCL [38]. In 1974, successful EM diagnosis was reported from
analysis of skin biopsies [39,40], which became thereafter themost com-
mon diagnostic instrument for NCL and a number of other neurodegen-
erative diseases of childhood. Rectal biopsy provides ready access to
neuronal tissue in themyenteric ganglia. The assessment of these by his-
tological and histochemical methods proved valid, and this led to the in-
troduction of EM analysis of rectal biopsies in NCL [41,42] which
overcame difﬁculties in differentiating by LM between storage material
and lipofuscin. This approach was very useful since it provided evidence
of accumulated storage product within the cytoplasm of extracerebral
neuronal cells, and it became recommended for selected cases in which
EM analysis of other tissues was not helpful. Moreover it contributed to
the abandonment of brain biopsies, at least in neurodegenerative child-
hood disorders. Then, the classiﬁcation of NCL was expanded by the rec-
ognition of subsets of patients by age of onset and clinical course
(infantile and early-juvenile onset) aswell as bynew cytosomepatterns
(GRODs and mixed cytosomes, respectively) [43,44]. The availability of
molecular tools by the end of the 1990s and the progressive identiﬁ-
cation of newNCL genes predicted a decline in the ultrastructural ap-
proach to diagnosis in NCL. However, ultrastructural examination of
extracerebral tissues is still necessary in atypical cases, particularly
the late-infantile variants (vLINCL), and the relatively stable ﬁgures
(10–15%) of molecularly undetermined cases. This is also particular-
ly true for the ultrastructural investigation of rectal biopsies in ANCL
because the detection of speciﬁc storage might be uncertain or poor,
or even missing in other extracerebral tissues [45]. Therefore, the
correlations among clinical features, genetic data, and EM ﬁndings
still represent useful tools to improve our knowledge and under-
standing of the pathobiology of this disease group [46]. Accordingly,
ultrastructural analysis of extracerebral tissues in the diagnosis of
NCL has been taken into account in a recent diagnostic algorithm
and included within an axial system of classiﬁcation [47].
4.2. General considerations
In this review we mainly focus on the EM features of skin biopsies
and blood lymphocytes, which are the best characterised extracerebraltissues for ultrastructural investigations in NCL; however, we have also
taken into account the ﬁndings from other biopsied tissues, such as the
rectum and, to a lesser extent, skeletal muscle. In extracerebral tissues,
cytosomes show the same patho-morphological and ultrastructural
characteristics as observed in CNS. Autoﬂuorescent, PAS and Sudan
black B-positive granules, resistant to lipid solvents, accumulate in
the cytoplasm of most cells. Interestingly, SCMAS is the major protein
storage detected in all NCL forms (other than CLN1) identiﬁed so far.
It is associatedwithmore variable EM features, CVPs, RLPs or FPPs, rem-
iniscent of the accumulation of adjacent membranes, the spatial distri-
bution of which is related to the physico-chemical properties of the
environment in which the abnormal material is stored [48]. Conversely,
SAPs are the main storage of CLN1 only, and are associated with the
GROD pattern, detected in this form.
EM studies of lymphocytes (obtained from gradient separation of
blood samples, subsequently ﬁxed and embedded) are particularly
recommended for the evaluation of patients clinically referred to as
having probable CLN1, CLN2 or CLN3, whose prevalent cytosomes
(GRODs, CVPs, FPPs, and vacuoles, respectively) can easily be detected
and can predict the mutated gene. In other NCL forms, namely vLINCL,
EM lymphocyte analysis may be less useful since lysosomal storage is
relatively nonspeciﬁc or scant when compared with themixed patterns
better detected in skin cells (Fig. 1). Lastly, the homogeneous lympho-
cyte cell population examined allows a semi-quantitative analysis,
which can be followed along the course of the disease, and whose var-
iations may represent a potential biomarker of disease progression.
Several advantages are obtained by examining a skin biopsy. First
of all, heterogeneous cell populations can be observed in skin tissue
and some cell type speciﬁcities can be recognised according to the
NCL form: for instance CVPs commonly crowd the smooth muscle
cells in CLN2, whereas vascular smooth muscle cells seem to be the
site of choice to detect the scarcely represented FPP in ANCL [49].
Moreover, the notion that cytosomes are more frequently heteroge-
neous in NCL variants, unrelated to primary lysosomal enzyme
deﬁciency, is consistent with the evidence that mixed storage prod-
ucts are readily detectable in skin elements [50]. Further advantages
come from the diagnostic investigation of skin. It may eventually be
possible to establish skin cell lines to support the identiﬁcation of
still missing NCL genes, for studies on pathogenesis from localization
and function of the mutated protein, or even for pharmacologic as-
says when the time approaches for possible speciﬁc treatments.
Nowadays, skeletal muscle is not used for ultrastructural examina-
tion in NCL because it has become evident that speciﬁc cytosomes are
not so easily detectable when compared to other biopsied tissues.
Skeletal muscle biopsies, primarily employed in the diagnosis of my-
opathies, are routinely utilised in the diagnosis of certain progressive
encephalopathies, when possible mitochondrial involvement is taken
into account. However, when this procedure is used for the differen-
tial diagnosis of neurodegenerative disorders (of childhood as well as
of adulthood), a search for autoﬂuorescent material and storage accu-
mulation should always be included because features consistent with
the diagnosis of NCL might be observed. To take the best advantage of
this procedure, therefore, samples frozen as well as embedded in
resin, should always be collected from the biopsied specimens. To
facilitate diagnostic interpretation in biopsied NCL extracerebral
tissues, a list of ultrastructural features that may be encountered in
a large variety of non-NCL conditions is listed in Table 1.
4.3. Childhood forms of NCL
4.3.1. CLN1
Mutations in CLN1, the gene encoding the enzyme PPT1, cause
classic CLN1 disease also known as infantile NCL [48,51]. Typically
the onset of the disease begins in infancy but as a result of different
mutations in the CLN1 gene, to date 49 different mutations have
been described, it is now recognised that the clinical course and age
Fig. 1. EM features of circulating lymphocytes in vLINCL patients: Similar cytoplasmic inclusions made up by granular and condensed osmiophilic inclusions in CLN5 (A, ×18,000) and
CLN8 (B, ×18,000) patients. FPP cytosomes (arrows) in a patient mutated in CLN7 (C, ×53,000). Mixed osmiophilic inclusions containing FPPs encircled by a single membrane in a
molecularly unidentiﬁed NCL patient (CLNX; D, ×135,000).
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venile and adult forms [52–54].
The diagnosis of CLN1disorder is based on an assay of enzyme activity
(PPT1/TPP1),molecular genetic testing andmorphological assessment of
biopsy samples. Accumulation of typical storage material occurs in
the central nervous system and retina and causes severe degenerative
changes which are most severe in the infantile form of CLN1. In other
sites storage is evident but destruction of the tissue is not a notable fea-
ture. It is from these more convenient sites that biopsy samples are
taken and examined, primarily by EM, for diagnostic conﬁrmation
of the disorder.
4.3.1.1. Histopathology. Extracerebral storage cytosomes are common-
ly seen in smooth and striated muscle, secretory epithelial cells espe-
cially those forming the eccrine sweat glands of the skin, vascular
endothelial and smooth muscle cells, ganglion cells of the enteric ner-
vous system and to a lesser extent circulating activated macrophages
and ﬁbroblasts. Samples for investigation have included rectal, conjunc-
tival and skeletalmuscle biopsies, but it is now commonly accepted that
skin biopsy and/or a blood sample for lymphocyte examination can
provide essential diagnostic information with minimal patient distress
[55].
4.3.1.1.1. Skin biopsy. Skin contains a diverse group of cell types
and is often the tissue of choice for the diagnosis of NCL and some
other lysosomal storage disorders. A 3 mm punch biopsy is easily
obtained from the inner aspect of the forearm or upper arm. A secondsample may also be taken for ﬁbroblast culture or DNA studies. Gen-
erally for histopathological examination the sample is processed en-
tirely for ultrastructural assessment as routine LM will not provide
conclusive or additional diagnostic information. Ideally the area to
be examined should include eccrine sweat glands, blood vessels and
small peripheral nerves.
4.3.1.1.2. Blood. Examination of blood lymphocytes by LM and EM
is a simple, minimally-invasive procedure to study NCL disease [56].
A blood ﬁlm can be assessed for vacuolated lymphocytes, normally
present only in CLN3 disease and some other lysosomal disorders
[57]. The remaining sample is centrifuged to form a buffy coat of
cells which is ﬁxed in glutaraldehyde and processed into resin for ul-
trastructural examination.
4.3.1.1.3. Rectal biopsy. Rectal biopsy can be used for the assess-
ment of NCL disease and other neurodegenerative disorders of child-
hood, however, it is now not the ﬁrst choice of biopsy. It contains a
diverse range of cells including neurons and nerves of the submucosal
and myenteric plexuses which may reﬂect some of the pathological
changes that are taking place in the CNS. Unfortunately suitable neu-
rons are not always present in the samples. Rectal tissue has also been
used for frozen sectioning which allows for enzyme histochemical
analysis and lipid demonstration.
4.3.1.1.4. Other tissue sites. Skeletal muscle biopsy has limited value
in the primary assessment of NCL disease and ultrastructural diagno-
sis may be difﬁcult to interpret as some storage inclusions such as
FPPs have not been described.
Fig. 3. Rectal biopsy — general LM features of CLN disease: Ganglion cells with dark blue
cytoplasmic storage granules. LFB ×160.
Table 1
Electron microscopic structures, differential diagnostic to neuronal-ceroid lipofuscinosis
(NCL) lipopigments.
Age-related or wear-&-tear lipofuscin
Lipopigments in vitamin-E deﬁciency
Residual bodies in other lysosomal diseases
(e.g. curved proﬁles in Farber disease, lamellar bodies and others)
Curvilinear proﬁles in chloroquine intoxication
Gall bodies in lymphocytes
Tubular arrays in lymphocytes
Undulating tubules/tubuloreticular proﬁles in endothelial cells
Pi-granules in Schwann cells
Weibel–Palade bodies in endothelial cells
Inclusions in duct cells of eccrine sweat glands
Inclusions in apocrine sweat gland cells
Granules in granulocytes
Granules in mast cells
Inclusions in melanocytes
Non-speciﬁc inclusions in macrophages
Inclusions of congenital myopathies in muscle ﬁbres
Polyglucosan bodies
Fingerprint-proﬁle inclusions in vascular smooth muscle cells
Non-speciﬁc dense bodies in terminal axons
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for this group of disorders but may have value in other lysosomal or
neurodegenerative disorders.4.3.1.2. Histochemistry and ﬂuorescencemicroscopy. The storage material
is generally robust enough to survive routine ﬁxation and parafﬁn pro-
cessing. The storage material shows a strong yellowish autoﬂuores-
cence with ultraviolet light (Fig. 2) but care must be taken to avoid
confusion with normal age related lipofuscin which tends to have a
more orange autoﬂuorescence. It may be examined by standard histo-
logical methods including PAS, LFB with cresyl violet counterstain
(Fig. 3) and lipid stains such as Sudan black B (Fig. 4). If frozen section
material is available, storage granules are strongly acid phosphatase
positive (Fig. 5) [43,58].4.3.1.3. Immunocytochemistry. Immunocytochemistry in CLN1 disease
should include antibodies to SAPs A and D, SCMAS and beta A4 amy-
loid protein. CLN1 can give a strong reaction for SAPs A and D, the
main component of storage material [59], a negative reaction for
SCMAS but may react with a monoclonal antibody against beta A4
amyloid protein [60].Fig. 2. Rectal biopsy — general light microscopy (LM) features of CLN disease: Rectal
ganglion cells showing yellowish autoﬂuorescent storage material with ultraviolet
light excitation. Unstained parafﬁn section. ×160.4.3.1.4. Electron microscopy. The storage cytosomes of CLN1 disease
are membrane-bound GRODs. The inclusions vary in size (0.5 μm to
3.0 μm in diameter) and shape and some may have an undulating
border with a distinct enclosingmembrane [43,58]. The internal gran-
ular material can be ﬁnely textured and compact, or, coarse and
loosely packed showing smaller globular subunits. The electron den-
sity of the material may also show some variation and can on occasion
be mistaken for other subcellular organelles.
GRODs are seen in various cells of the nervous system including
neurons, astrocytes and macrophages in the brain and spinal cord,
retinal cells and ganglion cells in the submucosal and myenteric plex-
us of the bowel.
4.3.1.4.1. Skin biopsy. The skin biopsy shows electron-dense stor-
age material mostly in secretory cells of eccrine sweat glands (Fig. 6)
and to a lesser extent in myoepithelial cells. Blood vessels in deeper
dermal regions also contain occasional deposits in endothelial (Fig. 7)
and smooth muscle cells. Those vessels near the epidermis are often
unrewarding. GROD may be present in erector pili muscle, ﬁbroblasts
and Schwann cells of the peripheral nerve.
4.3.1.4.2. Blood. Blood samples in CLN1 will demonstrate typical ly-
sosomal storage in 15–20% of lymphocytes in buffy coat preparations
(Fig. 8). This low yield may be due to the regular turnover of circulat-
ing lymphocytes or possibly a result of the very thin layer of section
examined ultrastructurally. It is therefore essential that at least 100
cells are examined to avoid false negative results [56]. Positive cells
contain one or two irregular proﬁles of GROD measuring up to 2 μm
at their greatest diameter (Fig. 9). EM also conﬁrms that there are no
vacuolated lymphocytes in CLN1.Fig. 4. Rectal biopsy — general LM features of CLN disease: Frozen section of rectal biopsy
showing lipopigment deposits in submucosal neurons and ﬁne droplets in smooth
muscle cells. Sudan black. ×160.
Fig. 5. Rectal biopsy — general LM features of CLN disease: Myenteric ganglion cells and
smooth muscle cells with positive staining of storage material. Frozen section. Acid
phosphatase. ×160. Fig. 7. CLN1: Skin biopsy blood vessel endothelial cell with loose texture GROD mate-
rial. EM ×8000.
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dothelial and smooth muscle cells of blood vessels, and in the often
abundant macrophages of the lamina propria, in rectal mucosal biop-
sy. Pure storage cytosomes will also be present in neurons but these
are generally of low electron density and ﬁnely granular in texture
(Fig. 10). Smooth muscle cell of the muscularis will display varying
amounts of storage material.
4.3.1.5. Prenatal diagnosis. Families with a known risk of CLN1 disease
can be offered prenatal diagnosis. A chorionic villus sample (CVS)
taken at 12–15 weeks of pregnancy can be examined biochemically
for the enzyme deﬁciency and ultrastructurally for storage inclusions.
In CLN1 disease GROD is present in subtrophoblastic blood vessel en-
dothelial cells. Since this can be sparse several vessels should be ex-
amined. The cytosomes have a loose texture and are 1 μm or less in
diameter (Fig. 11). In a series of CVS examined ultrastructurally [61]
this group describes positive ﬁndings in CLN1, CLN2, CLN3 and a var-
iant form, CLN6, which has subsequently been conﬁrmed by muta-
tional analysis (Guerreiro et al. 2012, personal communication). It is
advisable that if termination of pregnancy follows from a prenatal di-
agnosis, biochemical and EM examination of foetal tissues should be
requested. This is necessary both to provide conﬁrmation and support
to the family and for audit of laboratory procedures.
4.3.1.6. CLN1 — late-infantile and juvenile presentation. Several reports
have highlighted the later onset of CLN1 type disease caused byFig. 6. CLN1: Skin biopsy eccrine sweat gland epithelial cells with electron dense stor-
age deposits. EM ×5000.mutations in the CLN1/PPT1 gene with characteristic enzyme deﬁ-
ciency and ultrastructural deposition of GROD.
Ultrastructural features in these variant disorders include the familiar
storage cytosomes containing GROD. Extracerebral tissues have similar
characteristics and storage distribution to that seen in CLN1. There are
no vacuolated lymphocytes in the juvenile presentation and GROD is
the expected storage inclusion identiﬁed in lymphocytes. One group,
however, has reported a case showing lymphocytes with GROD com-
bined with CVPs or FPPs [62]. Examination of neurons from rectal biop-
sies has conﬁrmed the granular nature of the storage cytosomes. In
addition an associationwith small lipid or lipoprotein droplets is also de-
scribed. This feature is similar to the deposits seen in other examples of
variant NCL and dismissed by some workers as normal lipofuscin.
4.3.2. CLN2
Classic LINCL typically has an onset between the ages of two and
four years of age. It is characterised by mutations in the CLN2 or
TPP1 gene, which is located on chromosome 11p15 [63], resulting in
decreased lysosomal activity of TPP1. Many other forms of NCL have
a late-infancy onset including CLN5, CLN6, CLN7 and CLN8. These
are known collectively as vLINCL and are caused by other gene muta-
tions. Typically diagnostic assessment of CLN2 disease should include
enzyme assay (TPP1), molecular genetics and morphological assess-
ment. The choice of extracerebral biopsy has been discussed earlier
and applies to CLN2 disease as well.
4.3.2.1. Histopathology. Extracerebral tissues show no obvious histo-
pathological changes by LM but storage cytosomes are present andFig. 8. CLN1: Buffy coat lymphocytes with irregular GROD cytosomes. EM ×3000.
Fig. 9. CLN1: Lymphocyte with membrane bound GROD deposits. EM ×15,000.
Fig. 11. CLN1: CVS showing a single GROD cytosome in a subtrophoblastic blood
vessel endothelial cell. EM ×8000.
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storage is present and identiﬁed in rectal biopsy neurons which may
have a foamy appearance on haematoxylin and eosin staining. Smooth
muscle and endothelial cells also display punctate staining indicating
discrete storage inclusions that exhibit strong autoﬂuorescence. Eccrine
sweat glands of skin appear normal by routine LM but will display evi-
dence of positive staining for storage inclusions. This, however, cannot
be distinguished from the normal staining reaction of secretory cells
present in the area. Storage has also been identiﬁed in various endo-
crine tissues including the endocrine and exocrine cells of the pancreas.
4.3.2.2. Immunocytochemistry. Storage material in CLN2 disease shows
strong staining of SCMAS [64]. Immunoreactivity is preserved and can
be demonstrated in routine parafﬁn-processedmaterial allowing archi-
val review of stored material [65]. Increased reactivity for SAPs A and D
has also been documented with some inconsistent amyloid precursor
protein reactivity [60] but there is no evidence of ubiquitin reactivity.
4.3.2.3. Electronmicroscopy. Classic CLN2 disease shows pure CVPs in all
cells involved in the disease process. CVPs are uniformly curved short
thin lamellar stacks of alternating dark and light lines with minimal
variation in their overall shape. The lamellar proﬁles are surrounded
by a single membrane, conﬁrming the lysosomal nature of the disorder.
The CL proﬁles are in an electron lucent matrix and the enclosed struc-
ture forms a CVP body. CL storage in CLN2 disease is not associated
with other storage bodies or lipofuscin. The only exception to this is
the occasional fragmentary ﬁngerprint stacks that may be seen in CL
cytosomes in lymphocytes in CLN2 disease.
4.3.2.3.1. Skin biopsy. The presence of numerous pure CVP bodies
in secretory epithelial cells of eccrine sweat glands (Fig. 12), makesFig. 10. CLN1: Rectal biopsy neuron showing ﬁnely granular storage inclusions.
EM ×12,000.skin biopsy a preferred sample type for analysis. CVP inclusions are
also often located in endothelial and smooth muscle cells of blood
vessels (Fig. 13). Myelinated and small non-myelinated nerve ﬁbres,
surrounding sweat glands and blood vessels, occasionally demon-
strate storage cytosomes. Fibroblasts may also have CVP inclusions
in the cell body.
4.3.2.3.2. Blood. Blood buffy coat lymphocytes are not vacuolated in
CLN2 disease. Approximately 15–25% of lymphocytes show one or
two, irregular, membrane-bound CVP bodies (Fig. 14) of low electron
density with an indistinct ﬁngerprint stack (Fig. 15). For these rea-
sons examination of at least 100 cells is normally recommended.
4.3.2.4. Prenatal diagnosis. Prenatal diagnosis is generally provided by
enzyme assay and mutational analysis [66–68]. However EM of CVS
biopsy obtained at 12–15 weeks gestation can provide rapid, addi-
tional support. In CLN2 disease, discrete CVP inclusions have been
identiﬁed in subtrophoblastic blood vessel endothelial cells [61].
The larger blood vessels are more productive for identifying these
CVP inclusions (Fig. 16). If termination of pregnancy follows a prena-
tal diagnosis, biochemical assay and EM testing should be requested
from foetal tissues for conﬁrmation [69].
4.3.3. CLN3
JNCL or CLN3, the classical juvenile form of NCL is the most com-
mon disease variant, at least in Northern Europe, and has a worldwideFig. 12. CLN2: Skin biopsy epithelial cell with several pure membrane bound curvilin-
ear proﬁles. EM ×8000.
Fig. 13. CLN2: Dermal vascular smooth muscle cells with curvilinear proﬁles.
EM ×5000.
Fig. 15. CLN2: Curvilinear proﬁles with fragments of dense deposits. EM ×15,000.
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common being a 1.02 kb homozygous deletion), which encodes a
membrane protein pCLN3, predicted to have six transmembrane do-
mains spanning either the endoluminal or the cytosolic domains.
The protein is expressed ubiquitously and has been localised mostly
in the endosomal/lysosomal compartment, but is also recognised in
the synaptosomal fraction (in neuronal cells) and, to a lesser extent,
in the plasma membrane. There is evidence that any or all of a num-
ber of cell functions, including pH maintenance and osmoregulation,
membrane trafﬁcking, cell signalling, etc., are disrupted by mutations
in the CLN3 gene [71]. These exert negative effects on CNS cells specif-
ically, leading to selective cell death of neuronal subpopulations. Clin-
ical onset is by school age (5–8 years), visual failure being the main
presenting symptom in the vast majority of cases. Learning difﬁcul-
ties and behavioural disturbances usually follow, whilst motor symp-
toms, mental deterioration and seizures are relatively delayed. The
disease is deﬁnitively progressive, showing, however, different pat-
terns of evolution [72]. Death occurs during the late third/early fourth
decade in patients carrying the most common homozygous deletion
in the CLN3 gene, whereas longer survival is expected for compound
heterozygous patients. Cardiac involvement due to storage accumula-
tion, which affects the conduction system, is relatively common and
may lead to fatal arrhythmia; heart rhythm disturbances can, however,
beneﬁt from pacemaker ﬁtting [73].Fig. 14. CLN2: Lymphocyte with three curvilinear proﬁles. EM ×5000.4.3.3.1. Histopathology. Pathological features of extracerebral tissues
in classical JNCL/CLN3 have been of diagnostic use for decades, since
vacuolated lymphocytes were ﬁrst observed in blood smears stained
with modiﬁed Giemsa technique [74].
Enhanced histochemical activity of acid phosphatase, and pres-
ence of Sudan black positive material and of autoﬂuorescence can
be detected in some cell populations in skin biopsy (endothelial
cells, sweat gland epithelia, smooth muscle cells), in skeletal muscle
cells, and in ganglionic neurons (and surrounding cellular elements)
following rectal biopsy. Most of these cells are immunoreactive to an-
tibodies against SCMAS. Vacuolated cells can be better visualised
in semithin sections of biopsy samples or of buffy coat embedded
in resin, particularly lymphocytes and ganglionic neurons. Vacuoles
can look empty, or some solid material can be identiﬁed within them.
4.3.3.2. Electron microscopy
4.3.3.2.1. Blood. Ultrastructural analysis of blood lymphocytes is a re-
liable method to assess probable CLN3 patients. Either membrane-bound
empty vacuoles, or vacuoles containing dense material (usually FPP at
higher magniﬁcation) can be detected in at least 15–20% of cells, even
at the earliest stages of the disease; furthermore, isolated FPPs can be
detected in the cytoplasm (Fig. 17).
4.3.3.2.2. Other extracerebral tissues. Membrane-bound vacuoles
and cytosomes can be found in several other extracerebral tissues,Fig. 16. CLN2: CVS endothelial cell with rudimentary membrane bound curvilinear
proﬁles. EM ×10,000.
Fig. 17. CLN3 — blood lymphocytes: Ultrastructural features of lymphocytic vacuoles.
Multiple empty vacuoles of large size (A, ×23,500); smaller vacuoles containing
osmiophilic material of different features, including FPP (arrow); note free FPP in the
cytoplasm (arrowhead; B, ×37,000).
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tissue speciﬁcities (Fig. 18). In skeletal muscle, storage within the ﬁ-
bres commonly appears as RLP, whereas mixed FPP/RLP inclusions
can be observed in endothelial cells. In rectal mucosa, a mixed popu-
lation of cytosomes is also detected, along with FPP (within or outsideFig. 18. CLN3 — rectal biopsy: Vacuolated cytoplasm of ganglionic neurons (A, ×900);
orientation (B, ×113,000).vacuoles), packed concentric membranous cytoplasmic bodies can be
seen, featuring the same pattern as observed in gangliosidoses. The
presence of mixed inclusions (sometimes including CVP) can also be
present in skin elements.
4.3.3.3. Prenatal diagnosis. Prenatal diagnosis was reported by ultra-
structural analysis of chorionic villi (as well as aborted foetuses),
though diagnosis was difﬁcult based on stored material. In fact, follow-
ing a unique report showing FPP in the chorionic villi at 9th week of
gestation [74], inclusions containing lamellar material and membra-
nous fragments, but neither CVP nor FPP, were detected [75]. Such ﬁnd-
ings may represent the early stages of aggregation of storage material
before classical cytosomes are formed. This procedure has been re-
placed by molecular testing in at-risk pregnancies and for suspected
carriers.
4.3.3.4. Pathogenetic considerations. The patho-morphology of CLN3 dis-
ease is quite constant and no meaningful variations are detected
according to either the patterns of disease course or the kind of muta-
tions. The presence in several tissues of large vacuoles containing storage
material is consistent with activation of the autophago-lysosomal path-
way, and ultrastructural evidence of early autophagosome formation
can be detected even in biopsy material (AS, personal observations).
The relevance of this phenomenon in CLN3 (as compared to other CLN
diseases), indicates that autophagy is a major cellular event in this
human disease [76]. Whether disturbances of this process also play a
negative role in CNS neuron survival during the disease has not yet
been demonstrated. However, it was taken into account in the debate
over the mechanism of neuronal cell death in CLN3, since no evidence
of other cell-death patterns (such as apoptosis) has been demonstrated
in CLN3-deﬁcient mice. Rather, these show remarkable vacuolization of
the neuronal cytoplasm, consistent with impaired autophagosomemat-
uration and clearance [77,78].
4.3.4. CLN5
CLN5 disease is a rare vLINCL, ﬁrst described in Finland, and later
identiﬁed in several countries worldwide [7]. It occurs due to muta-
tions in the CLN5 gene, which codes for a soluble lysosomal protein,
whose function is not yet precisely known. It has recently been
suggested that it may play a role in controlling trafﬁcking from the
endoplasmic reticulum, (ER) through the Golgi apparatus, to the lyso-
somal compartment [79]. Clinical onset of CLN5 may be between 5
and 7 years of age and is late compared to other late-infantile forms.
It features either signs of psychomotor regression or early behavioural
abnormalities, and early speech disturbances. Seizures occur in all cases
but are not necessarily an early symptom.single membrane-limited vacuoles ﬁlled with FPP, showing prevalent semicircular
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straightforward approach towards molecular diagnosis difﬁcult and,
therefore, ultrastructural analysis of extracerebral tissues is commonly
performed ﬁrst, in order to recognise the presence (or absence) of stor-
age material. A mixed population of CVP and FPP lysosomal inclusions
are detected in skin cells in this condition. Either cytosomes can be
observed singly, affecting different cells of the same patient, or they
may occur as a complex structure containing both, CVP and FPP. RLP
and condensed osmiophilic material can also be present in this condi-
tion. Blood lymphocytes show lysosomal storage with nonspeciﬁc
features, such as granular material and condensed osmiophilic glob-
ules, commonly embedded in a homogeneous matrix; FPPs can also
be identiﬁed (Fig. 19). Single cytosome storage (namely of FPP) is
rare but it has been reported in two patients carrying different muta-
tions affected with early-juvenile and juvenile phenotypes [80,81].Fig. 19. CLN5 — skin biopsy: Osmiophilic inclusions scattered in the cytoplasm of differe
A, ×11,500); CVP outlined by a single membrane ﬁlling a ﬁbrocytic process (B, ×34,500); m
(C, ×70,500).Autophagic vacuoles were also described, which may suggest that
this process activates a possible rescue mechanism of the cell to get
rid of the abnormal storage [82].4.3.4.2. Prenatal diagnosis. Mixed cytosomes, featuring either CVP or
FPP, were reported in chorionic villi (pericytes and endothelial
cells) at 14th week's gestation [83] but molecular testing has largely
replaced EM analysis for prenatal diagnosis of CLN5.
Genotype–morphotype correlations are difﬁcult, due to the rela-
tively small number of reported patients. However, the kind of muta-
tion (either missense or nonsense) does not correlate with age of
onset, clinical severity, nor the quality of storage population; con-
versely, the clinical severity does seem to be partly related to the
quantity of mixed storage observed in the examined tissue.nt cells (asterisks); some of the inclusions are made up of FPP (see inset, ×72,000;
ixed population with a prevalent FPP component (asterisks) embedded in a loosematrix
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Mutations affecting the CLN6 gene are related to a wide phenotypic
spectrum as far as age of onset and disease duration are concerned.
CLN6 gene mutations can give rise to variant LINCL, to early JNCL,
as well as to ANCL (Kufs A type) [4,15]. The CLN6 gene encodes a
conserved, transmembrane polytopic protein of the ER (pCLN6) whose
function has yet to be identiﬁed. The relevance of the autophago-
lysosomal compartment observed in human ﬁbroblasts, however, sug-
gests that mutated pCLN6 may hamper lysosomal function. Mutations
in the CLN6 gene have worldwide distribution, with elevated frequency
in Southern European countries compared to those further North [84].
The clinical features of CLN6 disease of childhood onset are similar
to classical LINCL, and to vLINCL associated with mutations in the
CLN7 or CLN8 genes; with generalised seizures and motor symptoms.
The rate of disease progression may vary to some extent, with a rela-
tively slow andmore protracted course, but the disease symptoms are
similar to the other forms: motor impairment, myoclonic seizures,
speech degradation, visual loss, and mental deterioration, leading to
severe disability in mid-adolescence and death by the end of the sec-
ond decade in life. In CLN6-related vLINCL both electroretinogram
(ERG; response extinction) and evoked potentials (EP: giant cortical
EP) are abnormal [50].
4.3.5.1. Electron microscopy. Ultrastructural analysis of skin biopsy
or blood lymphocytes is useful, particularly during the early stages
of the disease. The cytosome pattern helps to discriminate between
cLINCL and vLINCL and determines, therefore, which biochemical path-
ways should be tested and/or genes sequenced. The storage population
in CLN6 disease is mixed and pleomorphic: CVP and FPP are the major
components with RLP, condensed osmiophilic bodies, and granularma-
terial less frequently seen. In skin biopsy, cytosomes can be detected
in any cell type, either as lysosomal structures or, less frequently, free
in the cytoplasm (Fig. 20). Smooth muscle cells can be affected, but
less heavily than in CLN2 disease. Vacuoles can be detected, either
empty or containing osmiophilic material of varying patterns, and
dilated cisternae of the ER are present. Cytoplasmic inclusions such
as granular or condensed bodies, or even RLP, can be seen in blood
lymphocytes.
4.3.5.2. Prenatal diagnosis. A recent report of ultrastructural ﬁndings in
a CVS in CLN6 found storage inclusions, in subtrophoblastic blood
vessel endothelial cells, that are amorphous and of medium electronFig. 20. CLN6 — skin biopsy: Double membrane vacuoles featuring autophagosome-like ﬁgu
and conformation embedded in ﬁnely granular matrix and outlined by a single membrane
plasm of a smooth muscle cell (arrows; B, ×58,000).density with occasional stacked lamellae. Subsequently, storage ma-
terial was conﬁrmed in the aborted foetus and the diagnosis of CLN6
established by mutation analysis (Guerreiro et al. 2012, personal
communication).
4.3.5.3. Pathogenetic considerations. The evidence of large vacuoles and
autophagosome-like structures is consistent with impaired function-
ing of the autophagic system in this condition [50]. At present there
is no evidence of genotype–phenotype correlations as far as the clin-
ical onset and disease course in CLN6 disease are concerned; likewise,
the reported mutations do not allow any genotype–morphotype rela-
tionship since the amount of storage and the relative heterogeneity of
the inclusions seem to be similar in all the reported cases.
4.3.6. CLN7
A severe vLINCL form is related to mutations in the CLN7 gene,
which codes for a transmembrane protein of the lysosomal mem-
brane, where it functions as a transporter, the substrate speciﬁcity
of which is still unknown [8]. Recently identiﬁed in Turkish kindreds
[85,86], it has also been described in patients of various ethnic origins,
but its frequency seems to be higher among many Mediterranean
populations [87]. As mentioned before, clinical presentation at onset
is similar to other LINCL, such as CLN2, CLN6 and CLN8. Generalised
seizures and developmental regression are present at onset, followed
by myoclonus, motor impairment with ataxia, speech and mental
deterioration, visual failure and characteristic behavioural and sleep
disturbances. The rate of progression is quite steady and the outcome
fatal within the second decade. Intrafamilial heterogeneity can be
present. Early involvement of the visual pathways is associated with
speciﬁc neurophysiological ﬁndings: occipital spikes during sleep
and possible photic response at EEG, giant occipital response follow-
ing visual EP, and ERG extinction.
4.3.6.1. Electron microscopy. Since the presenting clinical features of
CLN7 and other LINCLs are so similar, an ultrastructural approach
can indicate which biochemical and/or genetic assessment should
follow to achieve a differential diagnosis. Findings from skin, muscle
and rectal biopsies as well as blood lymphocytes have been reported
in CLN7 disease (Fig. 21). FPPs are the most frequently represented
cytosomes, seen in all of these tissues. They can be detected as single
storage bodies, or forming a mixed inclusion with either irregular
CVP, or RLP. Less evident than in other vLINCL is the presence ofres (asterisks); note a cytosome characterised by osmiophilic material of different size
(arrow; A, ×34,000); aggregated tubular proﬁles and FPP apparently free in the cyto-
Fig. 21. CLN7 — skin biopsy, smooth muscle cells: Mixed inclusions (RLP and FPP)
embedded in a dense matrix (A ×40,000) and CVP cytosomes (B, ×23,000).
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they do in cLINCL. Vacuolated lymphocytes are extremely rare and,
when present, the number of vacuoles in lymphocytes is remarkably
small.
4.3.6.2. Prenatal diagnosis. To date, no ultrastructural studies report
abnormalities in chorionic villi or foetal tissues.
Ultrastructural pathology is not suggestive of any abnormal cellular
process occurring due to CLN7 gene mutations. Both clinical features
and patterns of ultrastructural pathology are relatively homogeneous
in CLN7 disease and, therefore, there is no ﬁrm genotype–phenotype
correlation. Likewise, the patho-phenotype does not seem to be affected
by this kind of mutation.
4.3.7. CLN8
Twodifferent NCLswith different geographical distribution and clin-
ical evolution are grouped together under the term CLN8 disease [2].The mutated gene, CLN8, encodes a transmembrane protein of the ER,
which seems to function as a sphingolipid sensor and may be involved
in glycosphingolipid trafﬁcking [88]. CLN8wasﬁrst described in Finland
as progressive epilepsy withmental retardation (EPMR), also known as
Northern epilepsy syndrome. It is characterised by late-infantile onset
with epilepsy and cognitive decline, followed by relative clinical stabil-
ity and slow progression into adulthood. A genetic marker, a single
homozygous mutation in the CLN8 gene, has been identiﬁed in the
Finnish population. A panel of different mutations in the CLN8 gene
was later detected in a Turkish cohort of children also affected with a
late-infantile-onset disease. This allelic LINCL variant was recognised
to have a worldwide distribution [85,89]. In vLINCL CLN8, the age of
onset can be quite early (within the second year of life), with seizures
and progressive ataxia, followed by psychomotor regression andmyoc-
lonus. The visual system with retinal involvement is always affected,
with ERG extinction. Severe involvement of cortical structures is
outlined by the giant cortical potential elicited by EP. The outcome is
fatal by the end of the second decade.
4.3.7.1. Electron microscopy. Storage accumulation is characterised by
cytosome heterogeneity, detectable in different tissues (skin, lympho-
cytes, rectal mucosa), where a mixed CVP-FPP population is observed
within the lysosomes, commonly embedded in either a loose or granular
matrix. Both CVP and FPP can be detected separately, or may form a sin-
gle cytosome which contains both components. FPP can be observed
with classical membrane periodicity, condensed as osmiophilic globules,
or may show a loose pattern [90,91]. Other storage material may be
present, such as osmiophilic granules (particularly in the lymphocytes)
and RLP (Fig. 22). Such pathological heterogeneity is seen in both NCL
forms associated with CLN8mutations; vLINCL and EPMR. No vacuo-
lated lymphocytes are detected.
4.3.7.2. Prenatal diagnosis. Prenatal diagnosis by ultrastructural inves-
tigation has never been described.
A clinico-genetic correlation may be possible; there is evidence
that the most severe cases are associated with nonsense mutations
(leading to either no transcripts, truncated protein, or affecting a con-
served domain of pCLN8), but there is no clear relationship between
the pathological features (in terms of amounts of cytosomes, or ultra-
structural complexity) and the genotype.
4.3.8. CLN9
A small number of patients affected with a disease course similar
to classical JNCL, but without any known CLN3 gene mutation, have
been classiﬁed as “CLN9 type”. This rare form is associated with ab-
normalities in sphingolipid metabolism (in ﬁbroblasts), as well as
with decreased activity of dihydroceramide synthase. The mutated
gene associated with this condition remains unknown [92]. Vacuolat-
ed lymphocytes have been described, either empty, or containing
electron-dense storage with FPP pattern, but ﬁndings from other pe-
ripheral tissues have not been reported.
4.3.9. CLN10
CLN10 disease begins in utero, and this congenital disorder is a rare
and severe form in the spectrum of NCL disease which was ﬁrst de-
scribed in the early 1940s [93]. Its transmission is autosomal recessive
and it is caused by mutations in the CTSD gene (designated CLN10;
11p15.5) encoding the lysosomal enzyme cathepsin D [94,95]. It is
characterised by poor intrauterine foetal growth rate, microcephaly
and seizures [94]. Although the disease is rare many cases may be
undiagnosed as affected foetuses may be non-viable and are probably
spontaneously aborted or stillborn. There is no effective treatment for
congenital NCL and survival is a matter of hours or days, rarely longer.
Later onset forms of CLN10 have been reported in the literature
[95] and are thought to be due to partial inactivation of the CTSD
gene. This form of CLN10 has a more prolonged neurodegenerative
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inal atrophy.
Diagnosis of CLN10 is based on enzymatic testing for CTSD deﬁ-
ciency, granular storage material in tissue cells and molecular conﬁr-
mation of the CTSD gene mutation. CLN1/PPT1 deﬁciency should be
excluded as a possible differential diagnosis.
4.3.9.1. Electron microscopy. Skin biopsy ultrastructure from a patient
with late onset CSTD deﬁciency revealed granular storage material in
non-myelinated nerves. No storage material was identiﬁed in eccrine
sweat glands, or in ﬁbroblasts or endothelial cells [95]. This is an unusu-
al feature as in most other NCL disorders storage cytosomes are present
in many cell types.
Examination of a signiﬁcant number of peripheral blood lympho-
cytes from the same late onset CSTD patient showed no evidence of
storage material [95].
Experimental data suggest that in CSTD deﬁciency there is ultra-
structural degeneration of synaptic junctions leading to an increase
in releasable synaptic vesicles. CTSD is required for normal synaptic
function, and a failure in synaptic trafﬁcking or recycling may be an
early and important pathologic mechanism initiating synaptic degen-
eration in advance of subsequent neuronal loss [96].
4.3.9.2. Prenatal diagnosis. To date there are no published data on ul-
trastructural storage in prenatal samples. A novel mutation in the ca-
thepsin D gene, identiﬁed in one family, has been used to exclude
CSTD deﬁciency in a younger sibling of the affected patient [97].
4.3.10. CLN12
Four siblings with juvenile onset of NCL were found to have a
single homozygous mutation in the ATP13A2 gene, rendering thisFig. 22. CLN8 — skin biopsy: Fibrocytic processes (A, B, D); smooth muscle cell (C). He
(dark asterisks; A, ×26,000), globular cytosomes with round proﬁles (dark asterisk) an
(C, ×32,000); granular material embedded in a loose matrix (D, ×45,000).newly identiﬁed gene the cause of a new NCL form, CLN12. Lympho-
cytes showed vacuoles and, ultrastructurally, contained NCL-typical
lipopigments, which, by biopsy, were also seen in skeletal muscle [21].
4.3.11. CLN14
Siblings from three families from Mexico, Morocco and Turkey
with infantile onset (9–24 months of age), progressive myoclonic
epilepsy were found to have homozygous mutations in KCTD7, a gene
which encodes a potassium channel tetramerization domain containing
protein 7. Lysosomal storage products (GRODs and RLPs), detected in
peripheral blood lymphocytes and skin ﬁbroblasts of one patient,
were consistent with the inclusions detected in NCL. Therefore muta-
tions in KCTD7 can be associated with an infantile onset NCL, named
CLN14 [98].
4.3.12. Unidentiﬁed NCL/CLNX
In about 10–12% of patients affected with a progressive neurolog-
ical disorder, whose clinical and neurophysiological features are con-
sistent with a diagnosis of NCL, genetic mutations remain undeﬁned.
The age of onset of the disease in these patients is usually within the
range of the vLINCL, but later onset cases can also be observed. Ultra-
structural analysis of peripheral tissues shows the presence of
lipopigments and endolysosomal storage with heterogeneous pat-
terns, but rarely containing classical cytosomes (Fig. 23). The identi-
ﬁcation of new informative NCL families is therefore necessary in
order to recognise new NCL genes.
4.4. Adult forms of NCL
The usefulness of ultrastructural examination of extra-cerebral tis-
sues, as compared to brain biopsy, in ANCL is still debated [45,99]. Theterogeneous membrane-bound storage population: round, osmiophilic inclusions
d FPP (arrow; B, ×37,000), elongated cytosome ﬁlled with curvilinear-like proﬁles
Fig. 23. CLNX — skin biopsy and blood lymphocyte: A. Putative mixed cytosome population in the subaxonal space of an intradermal nerve ﬁbre (A, ×38,000); homogeneous
body with highly osmiophilic inclusions embedded in a smooth muscle cell (B, ×63,500); lipopigment storage in the cytoplasm of a blood cell (C, ×40,000).
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elements in several extracerebral tissues, has been reported over sever-
al decades [49,100], but is not a universal ﬁnding and so brain biopsy
might still be considered where extracerebral tissue yields negative
results [100]. Nonspeciﬁc lysosomal storage, such as lipopigmentmate-
rial, condensed osmiophilic bodies, etc., indicative of either lysosomal
storage or cellular products of the ageing process, can be readily detected
in different cell elements in the skin, skeletal muscle and rectal mucosa.
It is far more difﬁcult to detect speciﬁc NCL cytosomes such as RLP or
FPP in the skin or skeletalmusclewhichmay lead to false negative results,
but NCL cytosomes can be identiﬁed with less difﬁculty in the cytoplasm
ofmyenteric neurons in rectal biopsies. Therefore,we conclude that ultra-
structural investigation of rectal tissue is the best diagnostic approach in
ANCL, either to conﬁrm the diagnosis according to clinical and patho-
logical criteria, or to guide the molecular analysis of recently identiﬁed
ANCL genes.
4.4.1. Adult autosomal-recessive type of NCL
Autosomal recessive ANCL encompasses a group of disease whose
phenotypes span from classical Kufs A disease (characterised by progres-
sive myoclonus epilepsy (PME), with ataxia and cognitive deterioration
[101]) to other forms with earlier onset, prevalence of psychiatric symp-
toms, or late involvement, if any, of the visual system. To date, genetic–
pathological correlations have been established for autosomal recessive
ANCL forms, with mutations in CLN1, CLN5, CLN6, ATP13A2 and GRN
genes [13,15,54].
4.4.1.1. CLN1 — adult presentation. The ﬁrst cases of adult NCL with
PPT1 deﬁciency and GROD were reported in two sisters, presenting
at the ages of 31 and 38 years, with psychiatric symptoms only [54].
The same patients (at age 56 and 54 years), developed visual, verbal,
and cognitive losses, both had cerebellar ataxia and neither could walk
without support. The causative mutations in the CLN1 gene were R151X
and the novel missense mutation G108R.
Ultrastructural features in this variant disorder include storage
cytosomes containing GROD. Extracerebral tissues have similar char-
acteristics and storage distribution consistent with that seen in CLN1.Some adult patients, however, may present with GROD but neither
PPT1 nor CTSD deﬁciency [24].4.4.1.2. CLN5 — adult presentation. Two Caucasian patients with cogni-
tive regression and visual loss, of late adolescence onset, had com-
pound heterozygosity for mutations in CLN5. Both CVP and FPP
were detected in skin biopsy [13].4.4.1.3. CLN6— adult presentation. Adult onset CLN6 disease is less rare
than the previous forms. Patients have been described featuring the
Kufs A phenotype. Visual function is not affected in the adult form,
and no characteristic pattern can be observed by EP study. Phenotypic
heterogeneity can occur within the same family. Both homozygous
and heterozygous recessive mutations have been associated with
CLN6 patients [15].
In adult onset CLN6 disease, lipopigment material and condensed
osmiophilic bodies are frequently seen in different cell types in the skin
as well as in the skeletal muscle (Fig. 24). FPPs are rare but their pres-
ence is a strong incentive to search for mutations in the CLN6 gene. Ul-
trastructural analysis of rectal mucosa is more helpful in the diagnostic
work-up. Along with autoﬂuorescence in frozen or parafﬁn-embedded
samples, ultrastructural investigations of myenteric neurons will reveal
aggregates of FPP surrounded by a singlemembrane of lysosomal origin
(Fig. 25). This speciﬁc inclusion is often present in lipopigmentmaterial.
Other less speciﬁc storage both within the neuronal cytoplasm and in
that of other cell types, observed in rectal biopsy material, has been de-
scribed in post-mortem brain [15]. Vacuolated cells and dilated ER cis-
ternae can be detected in both skin and rectal biopsies. EM studies of
blood lymphocytes are not helpful.4.4.1.4. CLN11. Homozygous mutations in the progranulin gene GRN
have recently been reported in a family affected with adult onset pro-
gressive dementia and retinopathy. FPPs were detected in glandular
and endothelial cells of the proband's skin [102]. To date, this family
is the ﬁrst and only one revealing adult NCL with retinopathy.
Fig. 24. Adult CLN6: Skin (A–C) and skeletal muscle (D) biopsies in two adult patients mutated in CLN6. Fibrocytic processes containing round osmiophilic deposits of different size
(A and B) and stacks of osmiophilic material (B) embedded in a ﬁne matrix and lined by a single membrane; note dilated ER cisternae in A (A, ×36,000; B, ×64,000); mixed pop-
ulation (granular elements and RLP) in a cytosome (C, ×135,000); lipopigment storage (granular material and lipid droplet) in the subsarcolemmal space of a skeletal muscle ﬁbre
(D, ×28,500).
Fig. 25. Adult CLN6 — rectum: Osmiophilic storage material, either clustered or scattered
in the cytoplasmof amyenteric neuron (×9000),madeupof parallel stacks ofmembranes
forming FPP (Insert, ×90,000).
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Kufs B cases secondary to mutations in the cathepsin F gene [103]
are yet to be reported.
4.4.2. Adult autosomal-dominant type of NCL
Autosomal dominant adult onset NCL (Parry disease, CLN4) is a
rare condition (only a few families have been described so far),
characterised by generalised seizures, movement disorders and cog-
nitive deterioration followed by progressive dementia. Clinically, the
lack of myoclonus epilepsy and ataxia distinguish this disease from
Kufs A disease, the more common form of ANCL. The disease is asso-
ciated with heterozygous mutations of the DNAJC5 gene which en-
codes a cysteine-string protein alpha acting in synaptic vesicles
[29]. GRODs are the cytosomes observed in brain tissue and, to a less-
er extent, in extracerebral biopsies (including blood lymphocytes;
Fig. 26) [28,29].
4.5. Lipopigments in animals
To view ultrastructural ﬁndings of lipopigments in genetically dif-
ferent NCL species in the context of the overall ultrastructural spec-
trum of lipopigments, electron microscopic ﬁndings of lipopigments
in spontaneous animal models have been tabulated (Table 2), in par-
ticular as such animal models may – in the future – be employed in
therapeutic trials and, then, success or failure of treatment may not
only be judged by results of clinical investigations but may also, espe-
cially in smaller animals, be further corroborated by morphological
studies concerning increase or decrease in lipopigment load or alter-
ations in lipopigment ultrastructure.5. Outlook
Our knowledge of individual gene proﬁles and biochemistry of the
NCL disorders is expanding and providing further clariﬁcation of the
disease process. Examination of the morphology of storage products
in the CNS and other tissue sites is already informative and of diagnostic
Fig. 26. DNAJC5/CLN4: Rectal (A) and skin (B) biopsies in an adult patient mutated in DNAJC5. GRODs scattered in the cytoplasm of a myenteric neuron (A, ×26,000); GROD-like
elements associated with granular matrix in a smooth muscle cell (B, ×32,000).
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orders are being identiﬁed. The precise relationship between storage
cytosomes and the profound CNS damage is unclear. Also, we do not
have a clear reasoning as to why storage outside the nervous system
does not appear to cause tissue destruction or corresponding physiolog-
ical impairment.
Experimental work on animal models is providing some clues to
these dilemmas since knowledge gained might be extrapolated to the
human disease. However, without a detailed understanding of theTable 2
Ultrastructural proﬁles in spontaneous animal models of human NCL.
From Ref. [104].
Animal breed EM/ultrastructure Human gene
equivalent
Sheep New/South Hampshire
sheep
cl, fp, ml, crystalloid CLN6
Swedish Landrace sheep GROD CLN10/CTSD
Borderdale sheep cl, ml with fp CLN5
Cow Devon cattle cl, ml with fp CLN5
Cat Membranous whorls
straight+curved proﬁles, ml
Unknown
Dog American bulldog gr CLN10/CTSD
American Staffordshire
Terrier
Curved proﬁles ARSG
Australian Shepherd dog “Modiﬁed” cl CLN6
Border Collie fp, membranous, crystalloid CLN5
Dalmatian dog fp, cl, lamellar Unknown
English Setter fp, cl, lamellar CLN8
Longhaired Dachshund cl CLN2/TPP1
Dachshund gr CLN1/PPT1
Tibetan Terrier Lamellar ATP13A2
Miniature Schnauzer GROD Unknown
Ferret fp, cl, membranous Unknown
Goat fp, clm Unknown
Horse fp, cl, rl Unknown
Mouse ndf fp, cl, membranous CLN6
mnd rl, lamellar CLN8
Pig ml, cl, granular Unknown
cl, curvilinear. clm, concentric-laminated-membranous. gr, granular. fp, ﬁngerprint.
GROD, granular osmiophilic deposits. ml, multilamellar. rl, rectilinear.mechanisms underlying each form of NCL disorder, successful treat-
ment for this fatal disease will be hampered. Theremay be considerable
value in retrospective analysis, combining modern morphological, im-
munocytochemical, molecular and EM methodology, to review and
re-evaluate archived patient-derived samples.
As to future perspectives, it is unlikely that new brain biopsy ma-
terial will become available. Prospective post mortem studies, how-
ever, since NCLs are invariably fatal diseases, may yet yield more
information about selective or ubiquitous lipopigment formation as
well as neuronal loss and early microglial activation. In view of the in-
creasing availability of neuron-speciﬁc and intracellular antibodies,
even against lysosomal proteins, a wealth of new datamay be expected
from future postmortem studies and, as brain tissue obtained by autop-
sy and biopsy is usually archived in parafﬁn blocks, these new tech-
niques may be very gainfully employed retrospectively too.
Selective involvement of different grey matter regions has, so far,
only rarely been demonstrated [9]. Increasing awareness of the neu-
ronal periphery involved in NCL, marked by early microglial reactions
and subtle neuropathology in mouse models, begs the question
(on archival and future non-archival brain tissues) whether there is
correspondence (or lack thereof) among different brain regions of dif-
ferent genetic human forms of NCL and different mouse models. EM
studies of biopsied brain tissue, usually cerebral cortex, have focused
on lipopigment formation and ultrastructure, largely for diagnostic
purposes. A retrospective examination for research purposes may
focus more thoroughly on structural damage; concentrating on syn-
aptic contacts and the neuropathology of neuronal processes as well
as features of glial pathology. Thus, prospects for neuropathological
research investigations of human NCL brains are bright and promising
and ought to be vigorously pursued.
Histopathological and EM examinations of extracerebral tissues
and lymphocytes also remain essential adjuncts to the diagnostic
workup. These techniques remain central to the differential diagnosis
of NCLs from non-NCL neurodegenerative disorders and for determin-
ingwhich CLNmutationmay be present or likely. Careful microscopical
examination of lymphocytes for vacuolation, even where EM is not
available, is a rapid, inexpensive, and non-invasive diagnostic tool.
1824 G.W. Anderson et al. / Biochimica et Biophysica Acta 1832 (2013) 1807–1826Whilst DNA probes remain prohibitively expensive narrowing the
numbers of probes required is a major cost beneﬁt. There remains also
a large proportion of NCL cases for which gene mutations have yet to
be established, which cannot be identiﬁed by molecular methodology.
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